Get the Stockscreener App
74.61
3.17%
-2.445
Monopar Therapeutics Inc stock is traded at $74.61, with a volume of 246.27K.
It is down -3.17% in the last 24 hours and down -9.66% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$77.05
Open:
$76.51
24h Volume:
246.27K
Relative Volume:
1.99
Market Cap:
$498.55M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-32.44
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
-7.18%
1M Performance:
-9.66%
6M Performance:
+120.59%
1Y Performance:
+207.65%
1-Day Range:
$73.63
$76.89
1-Week Range:
$73.63
$83.86
52-Week Range:
$21.00
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
74.61 | 514.89M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - Defense World
Aug Catalysts: How interest rate cuts could boost Monopar Therapeutics Inc stockGap Up & High Accuracy Trade Alerts - moha.gov.vn
Monopar Therapeutics (NASDAQ:MNPR) Shares Up 6.3%Should You Buy? - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Will Monopar Therapeutics Inc. stock benefit from commodity prices2025 Winners & Losers & Safe Swing Trade Setup Alerts - Newser
Will Monopar Therapeutics Inc. (1IY0) stock rise with strong economyShare Buyback & Free Weekly Watchlist of Top Performers - Newser
How Monopar Therapeutics Inc. (1IY0) stock behaves in tightening cyclesJuly 2025 Setups & Consistent Growth Equity Picks - Newser
Is Monopar Therapeutics Inc. (1IY0) stock a safe buy pre earningsJuly 2025 Gainers & Verified Technical Signals - Newser
How (MNPR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Monopar Therapeutics (NASDAQ:MNPR) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
How Monopar Therapeutics Inc. (1IY0) stock correlates with oil markets2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Can Monopar Therapeutics Inc. (1IY0) stock stage a strong rebound this quarterRecession Risk & Risk Controlled Stock Alerts - Newser
Is Monopar Therapeutics Inc. (1IY0) stock worth buying before Fed actionMarket Activity Report & High Accuracy Investment Signals - Newser
Is Monopar Therapeutics Inc. stock a safe investment in uncertain markets2025 Support & Resistance & Entry Point Strategy Guides - moha.gov.vn
Monopar Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Free Rapid Portfolio Appreciation - earlytimes.in
Monopar Therapeutics (NASDAQ:MNPR) Shares Down 4%Time to Sell? - MarketBeat
What dividend safety score for Monopar Therapeutics Inc. stockNew Guidance & Free Technical Confirmation Trade Alerts - BỘ NỘI VỤ
Is Monopar Therapeutics Inc. stock a safe haven asset2025 Fundamental Recap & Weekly Breakout Watchlists - BỘ NỘI VỤ
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap UpHere's What Happened - MarketBeat
Monopar Therapeutics Unveils Promising Phase 2 Study Results - MSN
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - ADVFN
Trading Systems Reacting to (MNPR) Volatility - news.stocktradersdaily.com
Monopar Therapeutics Inc. (MNPR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is There An Opportunity With Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 46% Undervaluation? - simplywall.st
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? - Yahoo Finance
Monopar Therapeutics Shares Surge in Volatile Friday Session - Ad-hoc-news.de
Is Monopar Therapeutics Inc. stock a top momentum playTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
How geopolitical tensions affect Monopar Therapeutics Inc. stock2025 Institutional Moves & Growth Focused Investment Plans - newser.com
Will Monopar Therapeutics Inc. stock outperform Dow Jones indexMarket Volume Report & High Win Rate Trade Tips - newser.com
Why Monopar Therapeutics Inc. (1IY0) stock could be top winnerJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Why millennials buy Monopar Therapeutics Inc. (1IY0) stock2025 Support & Resistance & Free Fast Gain Swing Trade Alerts - newser.com
How Monopar Therapeutics Inc. (1IY0) stock expands through international marketsJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Can Monopar Therapeutics Inc. stock sustain market leadershipJuly 2025 Price Swings & Verified Trade Idea Suggestions - newser.com
What moving averages say about Monopar Therapeutics Inc.Weekly Gains Summary & Breakout Confirmation Trade Signals - newser.com
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingQuarterly Portfolio Summary & Growth Oriented Trading Recommendations - newser.com
Monopar Therapeutics Inc. stock prediction for this week2025 Pullback Review & Risk Controlled Daily Plans - newser.com
Is Monopar Therapeutics Inc. (1IY0) stock attractive for growth fundsJuly 2025 Analyst Calls & Free Long-Term Investment Growth Plans - newser.com
Will Monopar Therapeutics Inc. (1IY0) stock sustain dividend payouts2025 Trading Volume Trends & Weekly Top Gainers Alerts - newser.com
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):